Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Why Rheumatologists Should Care about Zika: How It’s Transmitted & Spreading in the U.S.

Lara C. Pullen, PhD  |  September 26, 2016

Rheumatologists are already familiar with one mosquito-borne virus, chikungunya, whose presentation mimics arthritis. Now, with its recent spread to Puerto Rico and the Southeastern U.S., Zika, another mosquito-borne virus, has become an international public health concern. Sexual transmission of the virus was recently confirmed, expanding the virus’s threat…

FDA Approves Adalimumab-atto, a Biosimilar of Humira

Reuters Staff  |  September 23, 2016

WASHINGTON (Reuters)—The U.S. Food and Drug Administration on Friday approved a cheaper, biosimilar version of AbbVie’s top-selling arthritis drug, adalimumab (Humira). The drug, adalimumab-atto (Amjevita), is made by biotechnology company Amgen Inc. and was approved to treat rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, psoriasis and other conditions. Amjevita is the fourth biosimilar to be approved…

How to Thrive—Not Just Survive—as a New Manager, Part 1

Karen Appold  |  September 23, 2016

The transition from employee to manager in a rheumatology practice can be daunting. But according to experts, setting clear roles and responsibilities and cultivating professional relationships with your employees ultimately help make you and the practice successful…

Celltrion Accelerates U.S. Launch of Infliximab-dyyb, a Remicade Biosimilar

Michele B. Kaufman, PharmD, BCGP  |  September 21, 2016

After winning the initial patent infringement lawsuit filed by Janssen, Celltrion Inc. is now shipping Inflectra (infliximab-dyyb), a biosimilar of Remicade (infliximab), to the U.S…

Is Arthroscopic Meniscal Surgery Effective?

Lara C. Pullen, PhD  |  September 19, 2016

A recent review examined the effectiveness of arthroscopic mensical surgery in treating meniscal injuries. Researchers determined that little evidence exists to support the use of arthroscopic meniscal surgery and more studies that directly compare it with nonoperative treatments are needed…

Novel Astrocytic Autoantibody Associated with Relapsing Meningoencephalomyelitis

Will Boggs, MD  |  September 18, 2016

NEW YORK (Reuters Health)—An autoantibody to glial fibrillary acidic protein (GFAP) is associated with relapsing autoimmune meningoencephalomyelitis that is responsive to immunotherapy, researchers report. “Autoimmune GFAP meningoencephalomyelitis is the second autoimmune neurological disease in which the target of the immune attack is recognized to be the astrocyte type of brain cell,” Dr. Vanda A. Lennon…

U.S. Justice Department to Push Prosecutors on Opioids

Reuters Staff  |  September 18, 2016

WASHINGTON (Reuters)—The U.S. Justice Department will enlist federal prosecutors to help fight the nation’s opioid crisis by sharing information on overprescribing doctors and coordinating with public health officials to address addiction, USA Today reported on Friday. “You can’t just have an enforcement strategy alone,” Attorney General Loretta Lynch told the newspaper in an interview. She…

Common Sense Tips for Rheumatologists on Social Media

Richard Quinn  |  September 16, 2016

Using social media goes beyond self-promotion, says David Deutsch. “If you can give prospective patients something that changes their lives, they will care about you.” A few thoughts on social media and rheumatology practices…

Abaloparatide Promising for Osteoporosis; NICE Draft Guidelines Include Secukinumab for Ankylosing Spondylitis

Michele B. Kaufman, PharmD, BCGP  |  September 14, 2016

In a clinical trial, subcutaneous abaloparatide has proved effective in treating postmenopausal women with osteoporosis. Also in the U.K., draft guidelines for treating ankylosing spondylitis will recommend the use of secukinumab…

Medicare Program Focuses on Rural Patients

Susan Bernstein  |  September 13, 2016

For arthritis patients who live in farming communities, just getting to rheumatologist Lynne Peterson, MD’s, office in Bismarck, N.D., can take a lot of time and energy. “Because of the shortage of rheumatologists, patients living in rural areas tend to receive inadequate rheumatologic evaluation and care,” says Dr. Peterson, whose clinic is located at Sanford…

  • « Previous Page
  • 1
  • …
  • 477
  • 478
  • 479
  • 480
  • 481
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences